UY38293A - Nuevos compuestos y composiciones de c-manósido antagonistas de fimh - Google Patents
Nuevos compuestos y composiciones de c-manósido antagonistas de fimhInfo
- Publication number
- UY38293A UY38293A UY0001038293A UY38293A UY38293A UY 38293 A UY38293 A UY 38293A UY 0001038293 A UY0001038293 A UY 0001038293A UY 38293 A UY38293 A UY 38293A UY 38293 A UY38293 A UY 38293A
- Authority
- UY
- Uruguay
- Prior art keywords
- compositions
- compounds
- new
- manoside
- fimh antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/02—Synthesis of the oxirane ring
- C07D301/03—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds
- C07D301/04—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen
- C07D301/08—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen in the gaseous phase
- C07D301/10—Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen in the gaseous phase with catalysts containing silver or gold
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695993P | 2018-07-10 | 2018-07-10 | |
| US201862755588P | 2018-11-05 | 2018-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38293A true UY38293A (es) | 2020-05-29 |
Family
ID=67957191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038293A UY38293A (es) | 2018-07-10 | 2019-07-08 | Nuevos compuestos y composiciones de c-manósido antagonistas de fimh |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11111262B2 (sr) |
| EP (1) | EP3820856B9 (sr) |
| JP (2) | JP7309862B2 (sr) |
| KR (1) | KR20210031682A (sr) |
| CN (1) | CN112334455B (sr) |
| AU (1) | AU2019301946B2 (sr) |
| BR (1) | BR112021000370A2 (sr) |
| CA (1) | CA3105940A1 (sr) |
| CL (1) | CL2021000033A1 (sr) |
| CY (1) | CY1125704T1 (sr) |
| DK (1) | DK3820856T3 (sr) |
| ES (1) | ES2928634T3 (sr) |
| HR (1) | HRP20221381T1 (sr) |
| HU (1) | HUE060140T2 (sr) |
| IL (1) | IL279993B2 (sr) |
| LT (1) | LT3820856T (sr) |
| MX (1) | MX2021000340A (sr) |
| MY (1) | MY201687A (sr) |
| PH (1) | PH12020551905A1 (sr) |
| PL (1) | PL3820856T3 (sr) |
| PT (1) | PT3820856T (sr) |
| RS (1) | RS63712B1 (sr) |
| SG (1) | SG11202011066XA (sr) |
| SM (1) | SMT202200435T1 (sr) |
| TW (1) | TWI821328B (sr) |
| UY (1) | UY38293A (sr) |
| WO (1) | WO2020012336A1 (sr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12269822B2 (en) | 2018-07-09 | 2025-04-08 | Boehringer Ingelheim Animal Health USA Inc. | Anthelminthic heterocyclic compounds |
| RS63712B1 (sr) * | 2018-07-10 | 2022-11-30 | Glaxosmithkline Ip Dev Ltd | Jedinjenja c-manozida korisna za tretman infekcija urinarnog trakta |
| MX2021011302A (es) | 2019-03-19 | 2022-01-19 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos. |
| CA3138394A1 (en) | 2019-05-07 | 2020-11-12 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| WO2021197363A1 (zh) * | 2020-03-31 | 2021-10-07 | 苏州大学 | 2-炔基甘露糖衍生物及其应用 |
| KR20230028268A (ko) | 2020-05-29 | 2023-02-28 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 헤테로시클릭 화합물 |
| US11999742B2 (en) | 2021-11-01 | 2024-06-04 | Boehringer Ingelheim Vetmedica Gmbh | Substituted pyrrolo[1,2-b]pyridazines as anthelmintics |
| WO2026077990A1 (en) | 2024-10-09 | 2026-04-16 | Glaxosmithkline Intellectual Property Development Limited | Novel use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5122602A (en) | 1989-02-13 | 1992-06-16 | Miles Inc. | Chromogenic merocyanine enzyme substrates |
| US6420127B1 (en) | 1994-11-18 | 2002-07-16 | Washington University | Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections |
| AU704114B2 (en) | 1993-11-18 | 1999-04-15 | Siga Technologies, Inc. | Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections |
| DE60006390T2 (de) | 1999-06-28 | 2004-05-13 | Lear Corp., Southfield | Verfahren zum formen eines blasgeformten kunststoffteils mit filmscharnier |
| WO2001010386A2 (en) | 1999-08-11 | 2001-02-15 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| WO2001095876A1 (en) | 2000-06-09 | 2001-12-20 | Baylor College Of Medicine | The combination of antimicrobial agents and bacterial interference to coat medical devices |
| EP1679299A1 (en) | 2003-10-08 | 2006-07-12 | Innovaprotean, S.L. | Compounds for the treatment of diseases associated with the formation of amyloid fibrils |
| EP1755619A2 (en) | 2004-03-23 | 2007-02-28 | VIB vzw | Anti-adhesive compounds to prevent and treat bacterial infections |
| SE528382C2 (sv) | 2004-10-05 | 2006-10-31 | Probi Ab | Probiotiska lactobacillusstammar för förbättrad vaginal hälsa |
| FR2876798A1 (fr) | 2004-10-14 | 2006-04-21 | Univ Clermont Auvergne | Diagnostic et traitement de la maladie de crohn |
| WO2011050323A1 (en) | 2009-10-22 | 2011-04-28 | The Washington University | Compounds and methods for treating bacterial infections |
| NZ616764A (en) | 2009-12-14 | 2014-11-28 | Univ Basel | Mannose derivatives as antagonists of bacterial adhesion |
| EP2672820B1 (en) | 2011-02-07 | 2019-04-17 | The Washington University | Mannoside compounds and methods of use thereof |
| WO2012164074A1 (en) | 2011-06-03 | 2012-12-06 | University Of Basel | Mannose phosphate derivatives as antagonists of bacterial adhesion |
| WO2013134415A1 (en) | 2012-03-07 | 2013-09-12 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
| EP2690105A1 (en) | 2012-07-24 | 2014-01-29 | Centre National De La Recherche Scientifique | Mannose derivatives, a process for preparing the same and their uses as a drug |
| US20150197536A1 (en) | 2012-07-28 | 2015-07-16 | The Regents Of The University Of Colorado, A Body Corporate | Compounds reducing the production of sorbitol in the eye and methods of using the same |
| WO2014055474A1 (en) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
| EP3388441A1 (en) | 2012-12-18 | 2018-10-17 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
| MX2015012472A (es) | 2013-03-12 | 2016-02-10 | Vertex Pharma | Derivados de manosa para el tratamiento de infecciones bacterianas. |
| CN105682665A (zh) * | 2013-05-30 | 2016-06-15 | 华盛顿大学 | 用于治疗细菌性感染的化合物和方法 |
| WO2017021549A1 (en) | 2015-08-05 | 2017-02-09 | Enterome | Mannose derivatives useful for treating pathologies associated with adherent e. coli |
| JP2019508504A (ja) * | 2016-03-11 | 2019-03-28 | フィンブリオン セラピューティックス, インコーポレイテッドFimbrion Therapeutics, Inc. | 疾病の処置に有用なc−グリコシド化合物 |
| AU2017238392A1 (en) | 2016-03-23 | 2018-09-27 | Fimbrion Therapeutics, Inc. | Mannose-derived antagonists of FimH useful for treating disease |
| WO2019076931A1 (en) | 2017-10-16 | 2019-04-25 | Enterome | NEW TOOLS FOR EVALUATING THE THERAPEUTIC EFFECTIVENESS OF FIMH BLOCKERS |
| RS63712B1 (sr) | 2018-07-10 | 2022-11-30 | Glaxosmithkline Ip Dev Ltd | Jedinjenja c-manozida korisna za tretman infekcija urinarnog trakta |
| CN109818150A (zh) | 2019-03-12 | 2019-05-28 | 信利半导体有限公司 | 一种液晶天线及其制作方法 |
-
2019
- 2019-07-08 RS RS20221021A patent/RS63712B1/sr unknown
- 2019-07-08 CA CA3105940A patent/CA3105940A1/en active Pending
- 2019-07-08 JP JP2021517745A patent/JP7309862B2/ja active Active
- 2019-07-08 LT LTEPPCT/IB2019/055806T patent/LT3820856T/lt unknown
- 2019-07-08 CN CN201980042125.1A patent/CN112334455B/zh active Active
- 2019-07-08 SM SM20220435T patent/SMT202200435T1/it unknown
- 2019-07-08 PT PT197692205T patent/PT3820856T/pt unknown
- 2019-07-08 HR HRP20221381TT patent/HRP20221381T1/hr unknown
- 2019-07-08 BR BR112021000370-3A patent/BR112021000370A2/pt unknown
- 2019-07-08 HU HUE19769220A patent/HUE060140T2/hu unknown
- 2019-07-08 AU AU2019301946A patent/AU2019301946B2/en active Active
- 2019-07-08 MX MX2021000340A patent/MX2021000340A/es unknown
- 2019-07-08 ES ES19769220T patent/ES2928634T3/es active Active
- 2019-07-08 MY MYPI2020005985A patent/MY201687A/en unknown
- 2019-07-08 IL IL279993A patent/IL279993B2/en unknown
- 2019-07-08 KR KR1020217000328A patent/KR20210031682A/ko active Pending
- 2019-07-08 EP EP19769220.5A patent/EP3820856B9/en active Active
- 2019-07-08 DK DK19769220.5T patent/DK3820856T3/da active
- 2019-07-08 UY UY0001038293A patent/UY38293A/es not_active Application Discontinuation
- 2019-07-08 WO PCT/IB2019/055806 patent/WO2020012336A1/en not_active Ceased
- 2019-07-08 SG SG11202011066XA patent/SG11202011066XA/en unknown
- 2019-07-08 TW TW108123912A patent/TWI821328B/zh active
- 2019-07-08 PL PL19769220.5T patent/PL3820856T3/pl unknown
-
2020
- 2020-10-06 US US17/063,947 patent/US11111262B2/en active Active
- 2020-11-06 PH PH12020551905A patent/PH12020551905A1/en unknown
-
2021
- 2021-01-07 CL CL2021000033A patent/CL2021000033A1/es unknown
- 2021-07-09 US US17/371,419 patent/US11697665B2/en active Active
-
2022
- 2022-10-03 JP JP2022159832A patent/JP7483820B2/ja active Active
- 2022-10-18 CY CY20221100686T patent/CY1125704T1/el unknown
-
2023
- 2023-04-28 US US18/308,842 patent/US12552824B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38293A (es) | Nuevos compuestos y composiciones de c-manósido antagonistas de fimh | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| UY38526A (es) | Inhibidores de kif18a | |
| EP3562514A4 (en) | GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE | |
| MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
| MX391624B (es) | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. | |
| GT201200315A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| MX388641B (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| MX2017006113A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
| EA201692334A1 (ru) | Кортикостероидные композиции для местного применения | |
| MX2018012230A (es) | Métodos para tratar enfermedades oculares. | |
| EP4003299A4 (en) | Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions | |
| EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
| SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
| EP3685840A4 (en) | PHARMACEUTICAL COMPOSITION OF COMPOUNDS FOR TREATING INFLAMMATORY SKIN DISEASES | |
| BR112017017599A2 (pt) | métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal | |
| MX2017015926A (es) | Uso de derivados de bencimidazol para escape acido nocturno. | |
| BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
| MX2018011539A (es) | Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas. | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| MA51278A (fr) | Utilisation d'un extrait végétal en tant qu'agent actif dans le traitement de maladies dermatologiques | |
| EP3603656A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF GYNECOLOGICAL DISEASES CONTAINING SARCODON IMBRICATUS EXTRACT AS ACTIVE INGREDIENT | |
| CR20110438A (es) | Icam 1 soluble como biomarcador para predicción de respuesta terapéutica | |
| MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201203 |